GLG News by Managed Care Experts

I disagree with the Reuters article. Tamiflu is a safe and effective drug for the young and elderly population.

It is very unlikely that 2% service fees for membership cards, and claims administration will match lost prohibited production and profit sharing revenue volume. September 2007 Ohio sues Zurich, Travelers, Chubb, Marsh Hartford and Ace on Anti Trust.  Carriers are insulated, but brokerage houses...

Most states have yet to weigh in on if, or how they will prosecute the big players on contingency fees, bid rigging and andor Antitrust.  Ohio just sued several defendants.  NY, IL, CT appear to have settled several issues with fines of $850, $91M, $51M, but we still need to hear from...

WalMarts strategy on expanding $4 generics is not at a loss.  They are taking a number of generics (in the hunderds) that are nominaly priced and selling them to consumers and still making a profit. 

Indian manufacturers such as Aurabindo, Reddy, Ranbaxy and others are getting on the shelves at the local pharmacies.

The Medicare Part D plans have proven extremely lucrative.  Wellcare has developed a good strategy that allows for enrollment and profitability.

Medical costs increasing at a rate greater than the annual rate of inflation have been a historical fact and should be expected until we get some fundamental changes in the way health care is delivered and managed in the United States.

While cost per capita is the highest in the world, why is our quality substandard?--Health care status is not solely based on healthcare and rejection of accountability of American people remains prevelant. More money is NOT the answer to what ails us in health care.

Health care cost increases remain unabated because they are not being managed. Employers behave as though they have no control over health care cost management Consumers are largely blind to the true cost of health care until they lose their insurance. Physicians suffer from stagnant fees because the...

European results in a limited number of patients on Exubera for 2-8 years Effectiveness and safety in about a 1/3 of study participants after 8 years